<p>Intellia Therapeutics（纳斯达克股票代码：NTLA - 获取免费报告）于周一公布了季度财报。该公司报告每股收益（EPS）为（$0.81），超出分析师一致预期的（$0.92）$0.11，FiscalAI 报道。Intellia Therapeutics 的净利润率为负 609.85%，股本回报率为负 56.81%。该公司本季度的收入为 1505 万美元，而分析师的预期为 1381 万美元。</p>
<p>获取 <strong>Intellia Therapeutics</strong> 的提醒：</p>
<h2>Intellia Therapeutics 价格表现</h2>
<ul>
<li>3 只可能受益于专利悬崖的生物科技股票</li>
</ul>
<p>周一中午交易时，NTLA 股票上涨了$0.64，达到了$14.73。该公司的股票交易量为 4,126,629 股，而其平均交易量为 5,303,502 股。Intellia Therapeutics 的 12 个月最低价为$6.83，最高价为$28.25。该公司的 50 日移动平均价格为$13.65，200 日移动平均价格为$12.41。该股票的市值为 17.7 亿美元，市盈率为-3.84，贝塔值为 1.93。</p>
<h2>分析师评级上调与下调</h2>
<p>多家券商对 NTLA 发布了报告。Truist Financial 在 3 月 25 日的研究报告中将 Intellia Therapeutics 的股票评级上调至 “强力买入”。William Blair 在 3 月 2 日的研究报告中将 Intellia Therapeutics 的股票评级从 “市场表现” 上调至 “跑赢大盘”。Robert W. Baird 在 4 月 27 日的研究报告中将 Intellia Therapeutics 的目标价从$7.00 上调至$13.00，并给予该公司 “中性” 评级。HC Wainwright 在 3 月 3 日的研究报告中将 Intellia Therapeutics 的目标价从$25.00 上调至$30.00，并给予该公司 “买入” 评级。最后，KeyCorp 在 1 月 28 日的研究报告中对 Intellia Therapeutics 设定了$25.00 的目标价。一位股票研究分析师将该股票评级为强力买入，九位分析师给予买入评级，十位分析师给予持有评级，三位分析师给予卖出评级。根据 MarketBeat.com 的数据，Intellia Therapeutics 的平均评级为 “持有”，平均目标价为$20.55。</p>
<ul>
<li>高盛在其看涨的标普 500 展望中关注这 3 只股票</li>
</ul>
<p><strong>查看我们最新的 Intellia Therapeutics 股票报告</strong></p>
<h2>机构投资者对 Intellia Therapeutics 的看法</h2>
<p>对冲基金和其他机构投资者最近增加或减少了对该公司的持股。Virtu Financial LLC 在第四季度收购了 Intellia Therapeutics 的新头寸，价值约为$245,000。Invesco Ltd.在第四季度将其在 Intellia Therapeutics 的持股增加了 5.8%。Invesco Ltd.目前拥有 433,290 股该公司的股票，价值$3,895,000，此前在上个季度又购买了 23,870 股。Axxcess Wealth Management LLC 在第四季度将其在 Intellia Therapeutics 的持股增加了 20.1%。Axxcess Wealth Management LLC 目前拥有 21,399 股该公司的股票，价值$192,000，此前在上个季度又购买了 3,583 股。Mercer Global Advisors Inc. ADV 在第四季度收购了 Intellia Therapeutics 的新头寸，价值约为$90,000。最后，XTX Topco Ltd 在第四季度收购了 Intellia Therapeutics 的新头寸，价值约为$402,000。目前 88.77% 的股票由机构投资者和对冲基金持有。</p>
<h2>Intellia Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<ul>
<li>分析师认为这些股票的价值可能翻倍</li>
</ul>
<p>Intellia Therapeutics, Inc. 纳斯达克：NTLA 是一家临床阶段的生物科技公司，专注于开发潜在的治愈性基因编辑疗法，使用 CRISPR/Cas9 平台。该公司的研究涵盖了 CRISPR/Cas9 的体内和体外应用，旨在通过一次给药纠正或禁用致病基因。Intellia 的主要体内项目针对转甲状腺素淀粉样变（ATTR），通过将 CRISPR/Cas9 机制直接输送到肝脏，而其他的临床前努力则追求治疗血友病 A、遗传性血管水肿和其他遗传疾病。</p>
<p>除了其体内管线，Intellia 还与战略合作伙伴合作，以扩大其基因编辑方法的影响。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票超过 Intellia Therapeutics</li>
<li>AI 分红增加：3 只巨头股票提升分红</li>
<li>疯狂的周一：这家 SaaS 领导者的反弹只是个开始</li>
<li>5 只有望受益于 AI 推理热潮的股票</li>
<li>Meta Platforms 的财报后剧烈波动：分析师的目标价现状</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlRMQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlRMQQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Intellia Therapeutics 吗？</h2>
<p>在你考虑投资 Intellia Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Intellia Therapeutics 并不在名单上。</p>
<p>虽然 Intellia Therapeutics 目前在分析师中评级为持有，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Intellia治疗

CRISPR治疗

基因免疫&健康关怀 ETF - iShares

<p>Intellia Therapeutics（纳斯达克代码：NTLA）报告的季度每股收益为（$0.81），超出预期的（$0.92）$0.11。该公司的收入为 1505 万美元，超过预期的 1381 万美元。Intellia 的净利润率为-609.85%，股本回报率为-56.81%。股票交易价格上涨至$14.73，市值为 17.7 亿美元。分析师的评级各不相同，其中一项为强烈买入，九项为买入，十项为持有，三项为卖出。机构投资者持有该股票的 88.77%，公司专注于 CRISPR/Cas9 基因编辑疗法</p>

<p>Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.92) by $0.11, FiscalAI reports. Intellia Therapeutics had a negative net margin of 609.85% and a negative return on equity of 56.81%. The firm had revenue of $15.05 million for the quarter, compared to analysts' expectations of $13.81 million.</p>
<div class="lb-trans"><p>Intellia Therapeutics（纳斯达克股票代码：NTLA - 获取免费报告）于周一公布了季度财报。该公司报告每股收益（EPS）为（$0.81），超出分析师一致预期的（$0.92）$0.11，FiscalAI 报道。Intellia Therapeutics 的净利润率为负 609.85%，股本回报率为负 56.81%。该公司本季度的收入为 1505 万美元，而分析师的预期为 1381 万美元。</p>
</div><p>Get <strong>Intellia Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Intellia Therapeutics</strong> 的提醒：</p>
</div><h2>Intellia Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Intellia Therapeutics 价格表现</h2>
</div><ul>
<li>3 Biotech Stocks That Could Benefit from the Patent Cliff</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只可能受益于专利悬崖的生物科技股票</li>
</ul>
</div><p>NTLA stock traded up $0.64 during midday trading on Monday, hitting $14.73. The company's stock had a trading volume of 4,126,629 shares, compared to its average volume of 5,303,502. Intellia Therapeutics has a twelve month low of $6.83 and a twelve month high of $28.25. The company's fifty day moving average price is $13.65 and its 200 day moving average price is $12.41. The stock has a market capitalization of $1.77 billion, a P/E ratio of -3.84 and a beta of 1.93.</p>
<div class="lb-trans"><p>周一中午交易时，NTLA 股票上涨了$0.64，达到了$14.73。该公司的股票交易量为 4,126,629 股，而其平均交易量为 5,303,502 股。Intellia Therapeutics 的 12 个月最低价为$6.83，最高价为$28.25。该公司的 50 日移动平均价格为$13.65，200 日移动平均价格为$12.41。该股票的市值为 17.7 亿美元，市盈率为-3.84，贝塔值为 1.93。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级上调与下调</h2>
</div><p>A number of brokerages have issued reports on NTLA. Truist Financial raised shares of Intellia Therapeutics to a &#34;strong-buy&#34; rating in a research note on Wednesday, March 25th. William Blair raised shares of Intellia Therapeutics from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating in a research note on Monday, March 2nd. Robert W. Baird raised their price objective on shares of Intellia Therapeutics from $7.00 to $13.00 and gave the company a &#34;neutral&#34; rating in a research note on Monday, April 27th. HC Wainwright raised their price objective on shares of Intellia Therapeutics from $25.00 to $30.00 and gave the company a &#34;buy&#34; rating in a research note on Tuesday, March 3rd. Finally, KeyCorp set a $25.00 price target on shares of Intellia Therapeutics in a research report on Wednesday, January 28th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, ten have assigned a Hold rating and three have assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Intellia Therapeutics has an average rating of &#34;Hold&#34; and an average target price of $20.55.</p>
<div class="lb-trans"><p>多家券商对 NTLA 发布了报告。Truist Financial 在 3 月 25 日的研究报告中将 Intellia Therapeutics 的股票评级上调至 “强力买入”。William Blair 在 3 月 2 日的研究报告中将 Intellia Therapeutics 的股票评级从 “市场表现” 上调至 “跑赢大盘”。Robert W. Baird 在 4 月 27 日的研究报告中将 Intellia Therapeutics 的目标价从$7.00 上调至$13.00，并给予该公司 “中性” 评级。HC Wainwright 在 3 月 3 日的研究报告中将 Intellia Therapeutics 的目标价从$25.00 上调至$30.00，并给予该公司 “买入” 评级。最后，KeyCorp 在 1 月 28 日的研究报告中对 Intellia Therapeutics 设定了$25.00 的目标价。一位股票研究分析师将该股票评级为强力买入，九位分析师给予买入评级，十位分析师给予持有评级，三位分析师给予卖出评级。根据 MarketBeat.com 的数据，Intellia Therapeutics 的平均评级为 “持有”，平均目标价为$20.55。</p>
</div><ul>
<li>Goldman Spotlights These 3 Stocks in Its Bullish S&amp;P 500 Outlook</li>
</ul>
<div class="lb-trans"><ul>
<li>高盛在其看涨的标普 500 展望中关注这 3 只股票</li>
</ul>
</div><p><strong>View Our Latest Stock Report on Intellia Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 Intellia Therapeutics 股票报告</strong></p>
</div><h2>Institutional Investors Weigh In On Intellia Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 Intellia Therapeutics 的看法</h2>
</div><p>Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Virtu Financial LLC acquired a new position in shares of Intellia Therapeutics during the 4th quarter worth about $245,000. Invesco Ltd. increased its stake in shares of Intellia Therapeutics by 5.8% during the 4th quarter. Invesco Ltd. now owns 433,290 shares of the company's stock worth $3,895,000 after purchasing an additional 23,870 shares during the last quarter. Axxcess Wealth Management LLC increased its stake in shares of Intellia Therapeutics by 20.1% during the 4th quarter. Axxcess Wealth Management LLC now owns 21,399 shares of the company's stock worth $192,000 after purchasing an additional 3,583 shares during the last quarter. Mercer Global Advisors Inc. ADV acquired a new position in shares of Intellia Therapeutics during the 4th quarter worth about $90,000. Finally, XTX Topco Ltd acquired a new position in shares of Intellia Therapeutics during the 4th quarter worth about $402,000. 88.77% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>对冲基金和其他机构投资者最近增加或减少了对该公司的持股。Virtu Financial LLC 在第四季度收购了 Intellia Therapeutics 的新头寸，价值约为$245,000。Invesco Ltd.在第四季度将其在 Intellia Therapeutics 的持股增加了 5.8%。Invesco Ltd.目前拥有 433,290 股该公司的股票，价值$3,895,000，此前在上个季度又购买了 23,870 股。Axxcess Wealth Management LLC 在第四季度将其在 Intellia Therapeutics 的持股增加了 20.1%。Axxcess Wealth Management LLC 目前拥有 21,399 股该公司的股票，价值$192,000，此前在上个季度又购买了 3,583 股。Mercer Global Advisors Inc. ADV 在第四季度收购了 Intellia Therapeutics 的新头寸，价值约为$90,000。最后，XTX Topco Ltd 在第四季度收购了 Intellia Therapeutics 的新头寸，价值约为$402,000。目前 88.77% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Intellia Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Intellia Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><ul>
<li>Analysts Think These Stocks Could More Than Double in Value</li>
</ul>
<div class="lb-trans"><ul>
<li>分析师认为这些股票的价值可能翻倍</li>
</ul>
</div><p>Intellia Therapeutics, Inc NASDAQ: NTLA is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company's research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia's lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.</p>
<div class="lb-trans"><p>Intellia Therapeutics, Inc. 纳斯达克：NTLA 是一家临床阶段的生物科技公司，专注于开发潜在的治愈性基因编辑疗法，使用 CRISPR/Cas9 平台。该公司的研究涵盖了 CRISPR/Cas9 的体内和体外应用，旨在通过一次给药纠正或禁用致病基因。Intellia 的主要体内项目针对转甲状腺素淀粉样变（ATTR），通过将 CRISPR/Cas9 机制直接输送到肝脏，而其他的临床前努力则追求治疗血友病 A、遗传性血管水肿和其他遗传疾病。</p>
</div><p>Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.</p>
<div class="lb-trans"><p>除了其体内管线，Intellia 还与战略合作伙伴合作，以扩大其基因编辑方法的影响。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Intellia Therapeutics</li>
<li>AI Dividend Increases: 3 Massive Winners Boosting Payouts</li>
<li>Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader</li>
<li>5 Stocks Positioned to Benefit From the AI Inference Boom</li>
<li>Meta Platforms’ Wild Post-Earnings Swings: Where Analyst Price Targets Stand Now</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 Intellia Therapeutics</li>
<li>AI 分红增加：3 只巨头股票提升分红</li>
<li>疯狂的周一：这家 SaaS 领导者的反弹只是个开始</li>
<li>5 只有望受益于 AI 推理热潮的股票</li>
<li>Meta Platforms 的财报后剧烈波动：分析师的目标价现状</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlRMQQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=NTLA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Intellia Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Intellia Therapeutics 吗？</h2>
</div><p>Before you consider Intellia Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑投资 Intellia Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intellia Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Intellia Therapeutics 并不在名单上。</p>
</div><p>While Intellia Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Intellia Therapeutics 目前在分析师中评级为持有，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Intellia Therapeutics（纳斯达克股票代码：NTLA）公布了财务业绩